World’s first cancer vaccine passes major test as tumour recurrence slashed by 42 per cent

The world’s first-ever cancer vaccine has slashed the risk of tumour recurrence by a staggering 42 per cent in clinical trials.

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.news.com.au)